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Editorial Commentary
Is the Deficiency of the Long Isoform of Cellular
FLICE-Inhibitory Protein Involved in Myocardial Remodeling?
Javier Díez, Arantxa Gonza´lez, Susana Ravassa
See related article, pp 1109–1117
The term “myocardial remodeling” is used to describe avariety of changes in cardiomyocyte and noncardiomyo-
cyte compartments of the myocardium that alter the geometry
and architecture of the left ventricular (LV) chamber and
occur in response to hemodynamic and neurohormonal
stress.1 Cardiomyocyte hypertrophy, apoptosis, and intersti-
tial and perivascular fibrosis are recognized as hallmarks of
myocardial remodeling.1 Because myocardial remodeling
may result in deterioration of both diastolic and systolic
function, propensity for arrhythmias, and compromise of
intramyocardial perfusion, it can be a key determinant of the
clinical course and outcome of a number of cardiac diseases.1
Therefore, there is a growing interest in gaining new insights
into the mechanisms responsible for cardiac remodeling, as
well as developing novel strategies aimed at prevention and
treatment.
In this conceptual framework, the study by Li et al2
published in the present issue of the journal provides new
information of great interest related to the cellular Fas-
associated death domain-like interleukin-1 converting en-
zyme (FLICE)-inhibitory protein (c-FLIP). This protein is a
catalytically inactive procaspase 8/10 homologue that asso-
ciates with the signaling complex downstream of death recep-
tors, negatively interfering with apoptotic signaling.3 Three
c-FLIP splice variants with differences in structure that reflect
distinct functional roles have been identified, the 24-kDa form
(c-FLIPR), the 26-kDa form (c-FLIPS), and the 55-kDa form
(c-FLIPL).3
Although most of the research on c-FLIP proteins has been
focused on their contribution to the development of tumors,
recent data also suggest a role in the heart. On the one hand,
it has been demonstrated that these proteins play a particu-
larly important role in the embryonic heart development.4 On
the other hand, Giampietri et al5 point to a role for c-FLIPL in
the cardiac response to hemodynamic stress. When c-FLIPL
transgenic mice overexpressing c-FLIPL in the heart were
subjected to pressure overload by transverse aortic constric-
tion, they showed normal LV function, reduced LV hyper-
trophy and fibrosis, and decreased induction of the cardiac
fetal gene program compared with wild-type mice. These data
have been expanded by Li et al2 using a cardiac model of
hormonal stress, chronic systemic infusion of angiotensin II
(Ang II) resulting in systemic hypertension. They show that,
after Ang II administration, heterozygous knockout mice for
c-FLIPL exhibit exacerbated cardiomyocyte hypertrophy and
myocardial fibrosis and more pronounced LV enlargement
and systolic dysfunction compared with wild-type mice.2 In
contrast, the histopathologic, geometric, and functional
changes induced by Ang II were attenuated in transgenic
mice with cardiac overexpression of human c-FLIPL com-
pared with control animals.2 Of interest, the protective effects
of c-FLIPL in transgenic mice were observed despite the
persistence of Ang II–induced hypertension. To support these
in vivo observations, the authors performed in vitro studies
and found that cFLIPL inhibits hypertrophy in rat cardiomyo-
cytes exposed to Ang II through direct inhibition of mitogen-
activated protein kinase kinase-extracellular signal-regulated
kinase 1/2 signaling.2 In addition, they reported that c-FLIPL
blocks collagen synthesis in rat cardiac fibroblasts by disrupt-
ing mitogen-activated protein kinase kinase-extracellular
signal-regulated kinase 1⁄2–dependent transforming growth
factor--Smad signaling. Collectively, these results suggest
that c-FLIPL can be a key regulator of the myocardial
response to mechanical and/or humoral injury.
Additional questions arise, as should be the case for such a
provocative study. One major question relates to apoptosis. Li
et al2 provide evidence that cardiac DNA fragmentation and
caspase 3, 8, and 9 activation after Ang II treatment increased
in c-FLIPL heterozygous mice compared with wild-type mice.
This aspect can be relevant because a dual role of c-FLIPL as
either inhibitor or activator of caspase 8 has now been
established, which may depend on a variety of parameters,
including cellular context and caspase 8:c-FLIPL ratio. For
instance, at low-level expression, c-FLIPL heterodimerizes
with procaspase 8 and caspase 8 autoprocessing, and activa-
tion occurs.6 In this regard, it is important to note that Li et al2
showed for the first time that c-FLIPL expression is down-
regulated during LV remodeling induced by chronic Ang II
infusion or transverse aortic constriction in normal mice.
Another major question concerns fibrosis. Myofibroblasts
are differentiated fibroblasts that express the highly contrac-
tile protein -smooth muscle actin and exhibit increased
migratory, proliferative, and secretory properties, thus being
currently considered as the cell type responsible for the
excessive synthesis and deposition of collagen fibers leading
to fibrosis.7 Recent evidence has suggested that differentia-
tion of fibroblasts occurs in response to Ang II and other
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cytokines and growth factors acting in a coordinated manner.7
Thus, it could be of interest to explore whether c-FLIPL
downregulation facilitates the differentiation of resident fi-
broblasts into myofibroblasts in the fibrotic myocardium.
From the above considerations, it can be hypothesized that
deficiency of c-FLIP proteins, in particular, the c-FLIPL
isoform, may facilitate myocardial remodeling in conditions
of hemodynamic overload or neurohormonal stress (Figure).
Interestingly, reduced c-FLIP expression has been described
in the myocardium of patients with end-stage heart failure
and rodents after myocardial infarction,8,9 2 conditions char-
acterized by severe myocardial remodeling. Therefore, al-
tered regulation of c-FLIP proteins can be of major impor-
tance for determining their contribution to myocardial
remodeling. Although c-FLIP expression can be regulated at
multiple levels, c-FLIP proteins have a short half-life in
normal cells, because their turnover is tightly controlled by
the ubiquitin-proteasome system.3 Because findings from a
number of studies suggest a role for increased ubiquitin-
proteasome system activity in the genesis of myocardial remod-
eling,10 the possibility exists that increased ubiquitin-proteasome
system–dependent degradation of c-FLIPL and other c-FLIP
isoforms may lead to diminished availability of these proteins
which, in turn, would facilitate the remodeling process.
In summary, Li et al2 should be congratulated for shedding
new light on the potential role of c-FLIPL in the development
of myocardial remodeling. Nevertheless, additional research
is required to achieve greater knowledge on the nature of
myocardial actions of this protein, as well as on its regulation
during cardiac diseases and its potential usefulness as a target
for therapeutic strategies aimed at preventing or repairing
myocardial remodeling.
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Figure. The imbalance between an excess of local deleterious mediators and a deficiency of local protective factors (including c-FLIP
proteins, eg, the long isoform c-FLIPL) may facilitate the development of myocardial remodeling in conditions of hemodynamic overload
or neurohormonal stress. Myocardial remodeling, in turn, can alter LV morphology and function, thus facilitating adverse cardiovascular
(CV) events and outcomes. ( means decreased availability and/or activity; , increased availability and/or activity.)
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